Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia.
about
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid LeukemiaWide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.Supportive care in patients with acute leukaemia: historical perspectives.Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantationHow low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology.A clinical challenge: Treatment of acute myeloid leukemia in a Jehovah's Witness.Comparing the ratio of mean red blood cell transfusion episode rate of 1 unit versus 2 units in hematopoietic stem cell transplant patients.Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis.Blood transfusion in hematologic intensive care unit.Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia.Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.Single versus double-unit transfusion policy in hematology.Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program.Acute myeloid leukemia in Jehovah Witnesses.
P2860
Q30238759-4CA1797A-E7F8-4DBB-B192-5D840E3E0B71Q33431399-711C2269-AF48-439F-9BA1-11DC3F363DDFQ33437019-E42A6934-B4E9-4E3A-A62C-C8CCA90EB060Q35265135-98F46E42-3F78-4CB4-98EA-D3334D063739Q35643058-9AF4295A-90BC-4CA2-BB6F-3E5516128308Q36945624-5973F88D-4ACD-496C-85F4-F8CD51576EF1Q37429209-70EDEAF6-67CF-4659-A53D-DE93887B80C0Q38915707-5DB3A101-9591-4702-B305-05AD290290AEQ39356470-AC50B06A-1B99-4AA3-9A57-1F1C87FF89F6Q40468838-5D467C1B-9104-4974-A94C-B92F18B2F94FQ40705792-F6394390-01DB-4B93-87B9-DEFE87067916Q40900632-81FCFAC5-7E27-4BAC-8D58-C86E4B4DA219Q43224599-2E4801AC-49B8-4DAA-9667-522DC2AAC0C1Q50203571-4BB32202-C23E-45FC-BE18-75360E6A4459Q51888823-DEC0AE64-C92A-429F-B365-A6F318EE0B09
P2860
Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@en
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@nl
type
label
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@en
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@nl
prefLabel
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@en
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@nl
P2093
P2860
P1433
P1476
Feasibility of a restrictive r ...... y for acute myeloid leukaemia.
@en
P2093
Caljouw MA
Schipperus MR
van Rhenen DJ
P2860
P356
10.1111/J.0958-7578.2004.00477.X
P577
2004-02-01T00:00:00Z